M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

A gastroenteropancreatic neuroendocrine tumor (GEP-NET) is a rare type of tumor that can grow in the pancreas or other areas of the gut, such as the stomach, small intestine, rectum, colon ...

Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...

MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of ...

Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z ...

Advanced Prostate Cancer Consensus Conference (APCCC) held in Lugano, Switzerland between April 25 th and 27 th was host to ...

The researchers’ studies detailed exactly how these laryngeal and tracheal neuroendocrine (NE) cells can sense water or acid in the upper airway and pass the information along by releasing ...

Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic ...

to include pediatric patients 12 years of age and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut ...

Novartis’ radioligand therapy Lutathera (lutetium Lu 177 dotatate) has been approved by the US Food and Drug Administration ...

A shocking cancer diagnosis and sudden surgery this year haven't stopped Phyllis Viagran from serving the South Side community.

Novartis (NVS) said that the U.S. Food and Drug Administration approved Lutathera for the treatment of pediatric patients 12 years ...